Mezomax Inc.

Mezomax a preclinical orthopedics focused company developing a small molecule drug to accelerate osteogenesis in fractures, osteoporosis and rare bone diseases.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded December 2017
  • Employees 5
  • Incorporation Type C-corp
  • Website mezomaxinc.com

Company Summary

We have developed a non-hormonal anabolic oral formulation that accelerates fracture healing by stimulating bone-forming cells through regulating calcium metabolism. This is a different and safer mechanism of action than the current standards of care in fracture healing and osteoporosis markets. Those products typically affect hormone and bone morphogenetic proteins induced signaling pathways leading to a plethora of possible adverse events.

Team

  • Kirill Susloparov
    CEO

    CEO and Founder of Mezomax Inc. CSU, Law degree. Financial management background. Experience establishing drug substance production and registration working as the CEO of the drug substance company.

  • Dmitriy Rybin
    President&CSO

    Ph.D. The developer of the drug and its production technology. Scientific supervisor of this business project. Solid-state chemistry and mechanochemistry expert. Senior Researcher of the Russian Academy of Sciences. He has 30+ years of Solid-State Chemistry experience working with mechanochemical and solvent-free technologies in drug design. Experienced in the pharmaceutical industry, animal studies, drug registration and international patenting.

  • Ilya Shmidt
    COO

    Physics, computer science. He joined Mezomax as a co-founder more than two years ago as a COO. He is responsible for all networking, communication, and operations.

Advisors

Previous Investors

  • Augustin Ku
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free